Skip to main content
Premium Trial:

Request an Annual Quote

BioView, ScreenCell Partner to Develop CTC Analysis Technology

NEW YORK (GenomeWeb News) – BioView and ScreenCell today announced a deal to develop a circulating tumor cell analysis technology.

The agreement seeks to combine ScreenCell's technology for isolating rare cells that may have prognostic and predictive value in cancer and BioView's scanning platform, which provides automated imaging and analysis solutions for rare cell and circulating tumor cell detection.

ScreenCell CEO David Znaty said in a statement, "Our objective is to support a breakthrough in personalized medicine by creating a non-invasive evaluation of specific therapeutic targets and 'real time' monitoring of target evolution which we strongly believe will be facilitated by combining ScreenCell and BioView technologies."

BioView is based in Rehovot, Israel and its Imaging Systems use field-proven algorithms and accommodate "both the need for CTC enumeration and retrieval of cellular and marker characteristics of captured cells," the company said.

Paris-based ScreenView's technologies isolate tumor cells by size and characterize them. The devices can be used for mesenchymal cells, cancer stem cells, microemboli, and cancer cells of non-epithelial origin.

Terms of the deal were not disclosed.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.